KB408
Gene therapy / editing
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
Serpentine-1 NCT06049082 · Alpha-1 Antitrypsin Deficiency Registry: NCT06049082 | 1 | To evaluate safety and tolerability of KB408 based upon assessment of adverse events (frequency, severity, relatedness), and changes from baseline in vital signs, ECG, spirometry, and clinical laboratory test results (2 months (Cohorts 1, 2, 3); 3 months (Cohort 2b)) 2025-12 | In progress: primary completion was expected 1 Dec 2025; results not posted | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Alpha-1 Antitrypsin Deficiency: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| KB408: this drug | Phase 1 | Gene therapy / editing | SERPINA1 (alpha-1 antitrypsin; gene replacement) | not yet graded | No reviewed efficacy summary in this indication | |
| Fazirsiran | Phase 3 | RNA / oligonucleotide | SERPINA1 | not yet graded | No reviewed efficacy summary in this indication | |
| Alvelestat | Phase 2 | Small molecule | Neutrophil elastase | Partial signal | NCT03636347: Blood neutrophil elastase activity reduced from baseline: -83.5% (SD 56.4) at alvelestat 120mg (p=0.023) and -93.3% (SD 41.0) at 240mg (p<0.001); both doses significant vs placebo (p<0.01 and p<0.001 respectively). | |
| BEAM-302 | Phase 1/2 | Gene therapy / editing | SERPINA1 PiZ mutation (E342K) | not yet graded | No reviewed efficacy summary in this indication | |
| TSRA-196 | Phase 1/2 | Gene therapy / editing | SERPINA1 | not yet graded | No reviewed efficacy summary in this indication | |
| WVE-006 | Phase 1/2 | RNA / oligonucleotide | SERPINA1 Z-allele mRNA (ADAR-mediated editing) | not yet graded | No reviewed efficacy summary in this indication | |
| Efdoralprin Alfa | —(overall) | Protein / enzyme therapeutic | Alpha-1 antitrypsin (AAT) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.